2CARE

2CARE is a 48 site, randomized, double-blind, placebo-controlled trial of coenzyme Q10 for the treatment of Huntington Disease (HD). The study enrolled 609 ambulatory subjects with HD who did not require skilled care or institutionalization. Eligible subjects were randomized to receive either CoQ 2400 mg/day or matching placebo. Subjects were followed prospectively and systematically for 60 months of double-blind observation. The primary outcome variable is a combination of time to death (for subjects who die) and the change from baseline to month 60 in Total Functional Capacity (TFC) score (for subjects who survive).

Detailed study information can be found here.